CSL – Citi rates the stock as Buy

By Broker News | More Articles by Broker News

As the company has lifted its guidance for the FY, Citi analysts have lifted their estimates and their price target to $215 from $175. High margins for Haegarda and Idelvion are the main drivers, they explain.

In Citi’s view, CSL remains a preferred name in the healthcare sector, which in itself is re-rating to higher valuations, due to the attractiveness of the plasma industry and the company’s estimated FY17-20 EPS CAGR of circa 20%. Buy.

Sector: Pharmaceuticals, Biotechnology & Life Sciences.

Target price is $215.00.Current Price is $182.95. Difference: $32.05 – (brackets indicate current price is over target). If CSL meets the Citi target it will return approximately 15% (excluding dividends, fees and charges – negative figures indicate an expected loss).

Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →